Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.38 |
| ▸ | ANTXR2 | P58335 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.37 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299449 | 0.97 | PAX8 (0.39) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL15833442 | 0.96 | PAX8 (0.39) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL16015593 | 0.96 | PAX8 (0.39) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL10177676 | 0.95 | PAX8 (0.43) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL16015605 | 0.93 | PAX8 (0.37) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL16299436 | 0.92 | PAX8 (0.41) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL13447794 | 0.91 | TSHR (0.47) | PAX8TSHRUSP2MEN1POLB | |
| SCHEMBL26167589 | 0.90 | PAX8 (0.43) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL16015594 | 0.90 | TSHR (0.38) | PAX8TSHRPRKCAAKT1PTK2 | |
| SCHEMBL26167587 | 0.90 | PAX8 (0.41) | PAX8TSHRPRKCAAKT1PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9370581-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-01-08 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | PAX8 4314/4885TSHR 2940/4885PRKCA 3608/4885 |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | PAX8 1029/4885TSHR 535/4885PRKCA 3016/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | PAX8 1006/4885TSHR 544/4885PRKCA 3027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.